deaths (OS)

mML - L1 - all population metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - all population

versus ipilimumab alone
nivolumab plus ipilimumab vs. ipilimumab alone 2 statistically conclusive-38%
versus nivolumab alone
nivolumab plus ipilimumab vs. nivolumab alone 1 certainty unassessable-32%
relatlimab plus nivolumab vs. nivolumab alone 1 -

mML - L1 - BRAF mutant metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - BRAF mutant

versus ipilimumab alone
nivolumab plus ipilimumab vs. ipilimumab alone 1 certainty unassessable+44%

mML - L1 - BRAF wild metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - BRAF wild

versus ipilimumab alone
nivolumab plus ipilimumab vs. ipilimumab alone 1 -